Seeking Patients Diagnosed with NSCLC


We are looking for Patients diagnosed with NSCLC Stage III for a 15-minute online survey paying $35.00 followed by a 60-minute telephone interview paying $150.00 for a total of $185.00.


  • Must have been diagnosed with NSCLC Stage III
  • Patient must be 18 – 78 years old
  • CANNOT have any diseases or conditions that makes it difficult for you to breathe to qualify
  • MUST have discussed undergoing treatment for lung cancer with your Doctor to qualify

If you do not meet the above criteria you will not be selected for this study, but we STILL want to hear from you! Please join our patient panel by CLICKING HERE

Who Are We (Echo Project Management Group, Inc.)

  • We are a leader in connecting patients with recognized medical Research Studies
  • We are dedicated to being up front and open with you. If you have questions just ask!
  • We are committed to protecting your personal data and are a HIPAA Compliant Entity

Patients Will be Compensated for Their Time

If you meet the above qualifications we want to hear from you! Please enter the requested information below and you will be contacted by one of our representatives

We (ECHO PMG) will comply with all US laws in protecting your personal data, and also in accordance with BHBIA guidelines and the MRS/EphMRA, PBIRG and ABPI codes of conduct.   Your responses will be collated with those of other patients and presented to our client in aggregated or anonymous form; your identity will not be revealed.  Your responses will be otherwise confidential and will not be used for any other purposes or disclosed to any third party without your approval.

1 Chemotherapy provided during this stage may include: Carboplatin, Carboplatin + pemtrexed, Cisplatin, Cisplatin + e [be consistent with capitalisation] toposide, Cisplatin + pemetrexed, Cisplatin + vinblastine, Cyclophosphamide, Docetaxel, Doxorubicin,  Etoposide, Gemcitabine, Nab-Paclitaxel, Oxaliplatin, Paclitaxel, Paclitaxel + c [per previous comment] arboplatin, Pemetrexed, Vinblastine, Vincristine, Vinorelbine. [Please be consistent with using brand name as relevant to be consistent with use of brand names – see checkpoint inhibitors below]
Please note this listing was compiled for examples based on common regimens and/or single agents prescribed at stage III NSCLC based on Ipsos data in the United States from Q1 2018, and not necessarily meant to be exhaustive.
2 Check-point inhibitor therapy/immunotherapy e.g., durvalumab (IMFINZI), pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), ipilimumab (Yervoy)
3 Biologic therapy therapy  e.g., Alectinib (Alecensa), Atezolizumab (Tecentriq),  bevacizumab (Avastin), Ceritinib (Zykadia), ramucirumab (Cyramza),  osimertinib (Tagrisso), gefitinib (Iressa), erlotinib (Tarceva), crizotinib (Xalkori), ceritinib (Zykadia), Afatinib (Gilotrif), Dabrafenib (Tafinlar),Rituximab (Rituxan), Trametinib (Mekinist)